Nigrostriatal upregulation of 5-HT2A receptors correlates with motor dysfunction in progressive supranuclear palsy

Movement Disorders

Volumn 24, Issue 8, 2009, Pages 1170-1175

  Stamelou, Maria ^a,b   Matusch, Andreas ^a,b   Elmenhorst, David ^a   Hurlemann, René ^c   Eggert, Karla M ^b   Zilles, Karl ^a,d   Oertel, Wolfgang H ^b   Höglinger, Günter U ^b   Bauer, Andreas ^a,d  

^a FORSCHUNGSZENTRUM JÜLICH   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

5 HT; 5 HT2A receptor; PET; PSP; Serotonin; Steele Richardson Olszewski syndrome

Indexed keywords

ALTANSERIN; FLUORINE 18; SEROTONIN 2A RECEPTOR;

ADULT; ARTICLE; BINDING AFFINITY; BRAIN CORTEX ATROPHY; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE ASSOCIATION; FEMALE; FUNCTIONAL ASSESSMENT; GRAY MATTER; HUMAN; INSULA; MALE; MOTOR DYSFUNCTION; NIGRONEOSTRIATAL SYSTEM; ORBITAL CORTEX; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; RECEPTOR UPREGULATION; SUBSTANTIA NIGRA; UNIFIED PARKINSON DISEASE RATING SCALE;

AGED; BRAIN MAPPING; CORPUS STRIATUM; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; KETANSERIN; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MOVEMENT DISORDERS; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, SEROTONIN, 5-HT2A; STATISTICS AS TOPIC; SUBSTANTIA NIGRA; SUPRANUCLEAR PALSY, PROGRESSIVE; UP-REGULATION;

EID: 67651156120     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22533     Document Type: Article

References (18)

1. Rajput A, Rajput AH. Progressive supranuclear palsy: clinical features, pathophysiology and management. Drugs Aging 2001; 18:913-925.
2. Warren NM, Piggott MA, Perry EK, Burn DJ. Cholinergic systems in progressive supranuclear palsy. Brain 2005;128:239-249.
3. Litvan I, Agid Y, Jankovic J, et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology 1996;46:922-930.
4. Hornykiewicz O, Shannak K. Brain monoamines in progressive supranuclear palsy-comparison with idiopathic Parkinson's disease. J Neural Transm Suppl 1994;42:219-227.
5. Kovacs GG, Kloppel S, Fischer I, et al. Nucleus-specific alteration of raphe neurons in human neurodegenerative disorders. Neuroreport 2003;14:73-76.
6. Chinaglia G, Landwehrmeyer B, Probst A, Palacios JM. Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study with [3H]citalopram. Neuroscience 1993;54: 691-699.
7. Landwehrmeyer B, Palacios JM. Alterations of neurotransmitter receptors and neurotransmitter transporters in progressive supranuclear palsy. J Neural Transm Suppl 1994;42:229-246.
8. Castro ME, Pascual J, Romon T, Berciano J, Figols J, Pazos A. 5-HT1B receptor binding in degenerative movement disorders. Brain Res 1998;790:323-328.
9. Pascual J, Figols J, Grijalba B, et al. Changes in aminergic receptors in a PSP postmortem brain: correlation with pathological findings. J Neural Transm Suppl 1994;42:247-260.
10. Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain 2007;130:1552-1565.
11. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology 2000;55:1621-1626.
12. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389.
13. Hurlemann R, Matusch A, Kuhn KU, et al. 5-HT2A receptor density is decreased in the at-risk mental state. Psychopharmacology (Berl) 2008;195:579-590.
14. Pinborg LH, Adams KH, Svarer C, et al. Quantification of 5-HT2A receptors in the human brain using [18F]altanserin-PET and the bolus/ infusion approach. J Cereb Blood Flow Metab 2003;23:985-996.
15. Brenneis C, Seppi K, Schocke M, Benke T, Wenning GK, Poewe W. Voxel based morphometry reveals a distinct pattern of frontal atrophy in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2004;75:246-249.
16. 3H]MDL100,907 autoradiography and in situ hybridization studies. J Comp Neurol 2001;429:571-589.
17. Ikemoto K, Nishimura A, Okado N, Mikuni M, Nishi K, Nagatsu I. Human midbrain dopamine neurons express serotonin 2A receptor: an immunohistochemical demonstration. Brain Res 2000; 853:377-380.
18. 2A receptors are increased in Parkinson's disease neocortex. Ann N Y Acad Sci 1998;861:288-289.